- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06307340
Tilpasning av STAIR-NT Trauma Intervention for Polysubstance Populations
During this 36-month R34 trial, eight study phases are proposed to adapt an evidence-based post traumatic stress disorder (PTSD) intervention (STAIR-NT) and layer it into a methadone maintenance treatment (MMT) program (START Treatment and Recovery centers) in New York City for use among individuals engaged in stimulant-opioid polysubstance use. The study aims to adapt STAIR-NT to a massed treatment schedule. Once an adapted protocol is complete, it will be tested for feasibility, acceptability, and short-term polysubstance and PTSD symptomology outcomes in a pilot randomized control trial (RCT) of 80 participants. Participants who screen eligible and consent will be randomized 1:1 to the adapted STAIR-NT intervention or treatment as usual (TAU) using randomization blocks of two and two and four via a computer-generated randomization sequence. Participants assigned to the intervention will receive the adapted massed delivery of STAIR-NT by trained counselors.
Studieoversikt
Status
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Florida
-
Tallahassee, Florida, Forente stater, 32306
- Florida State University
-
-
New York
-
Brooklyn, New York, Forente stater, 11238
- START Treatment and Recovery Centers
-
New York, New York, Forente stater, 10016
- NYU Langone Health
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- must be 18 years or older,
- be a patient at the START clinic receiving methadone for treatment of opioid use disorder,
- self-report 10+ days of co-use of cocaine and illicit opioids in the past 30-days,
- meet the criteria for stimulant use disorder (cocaine type; mild, moderate or severe) and a score of 3≥ on the PC-PTSD-5.
Exclusion Criteria:
- cognitive impairment that would interfere with their ability to understand study participation as assessed by the researcher,
- does not speak/understand English at a conversational level,
- plans to leave the START clinic in the next 60 days,
- patients who missed methadone doses (inactive) for 30 days or more, or
- having received clinical care from the interventionist(s) in the past 30 days
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Helsetjenesteforskning
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Behandling som vanlig (TAU)
|
Treatment as usual. |
|
Eksperimentell: Tilpasset STAIR-NT Intervensjon
|
Adapted version of evidence-based behavioral PTSD intervention. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Antall fullførte intervensjonsøkter
Tidsramme: Opp til måned 3
|
Opp til måned 3
|
|
|
Antall stoffer som er brukt basert på undersøkelse av urinmedisin
Tidsramme: Måned 3
|
Måned 3
|
|
|
Antall stoffer brukt basert på diagramabstraksjon av toksikologiske resultater
Tidsramme: Måned 3
|
Måned 3
|
|
|
Proportion of Eligible Participants
Tidsramme: Baseline
|
Proportion of persons eligible to enroll in the study of all possible MMT patients approached. Assessed using count data of individuals failing screen. |
Baseline
|
|
Proportion of Eligible Participants who Enroll
Tidsramme: Baseline
|
.Proportion of all eligible persons who enroll. Assessed using count data of individuals consented. |
Baseline
|
|
Clinician-Rated Feasibility of Intervention Measure (FIM) Score
Tidsramme: Month 3
|
4-item, clinician-rated assessment of the feasibility of the intervention. Each item is rated on a scale from 1 (Completely disagree) to 5 (Completely agree); the total score is the sum of responses and ranges from 4-20. Higher scores indicate greater clinician-rated feasibility. |
Month 3
|
|
Clinician-Rated Feasibility of Acceptability of Intervention Measure (AIM) Score
Tidsramme: Month 3
|
4-item, clinician-rated assessment of the acceptability of the intervention. Each item is rated on a scale from 1 (Completely disagree) to 5 (Completely agree); the total score is the sum of responses and ranges from 4-20. Higher scores indicate greater clinician-rated acceptability. |
Month 3
|
|
Number of Days of Co-Use of Cocaine and Illicit Opioids
Tidsramme: Month 3
|
Measured using the Addiction Severity Index (ASI) questionnaire. |
Month 3
|
|
Number of Substances Used based on ASI Self-Report
Tidsramme: Month 3
|
Measured using the Addiction Severity Index (ASI) questionnaire, a self-report assessment to gauge the severity of a person's substance abuse. |
Month 3
|
|
PTSD Checklist for DSM-5 (PCL-5) Score
Tidsramme: Month 3
|
The PCL-5 is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD. Each item is rated on a scale from 0-4. A total symptom severity score (range - 0-80) can be obtained by summing the scores for each of the 20 items; higher scores indicate greater severity of PTSD. |
Month 3
|
|
Negative Mood Regulation Scale Score
Tidsramme: Month 3
|
30-item assessment of individuals' beliefs and expectations regarding their ability to regulate their negative mood and emotions. Each item is rated on a 5-point Likert scale ranging from 1 (not at all effective) to 5 (extremely effective). The total score ranges from 30-150; higher scores indicate more effective negative mood regulation. |
Month 3
|
|
Inventory of Interpersonal Problems Score
Tidsramme: Month 3
|
A 127-item, self-report inventory that asks participants to rate a variety of interpersonal problems that may cause distress. The items are divided into two groups: (1) interpersonal inadequacies or inhibitions (78 items), (2) excesses or compulsions (49 items). Participants rate each item on a scale from 0 to 4 on how much difficulty/distress they feel regarding the item. The total score is calculated by adding the item responses; lower scores indicate less difficulty/distress. |
Month 3
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Amanda Bunting, NYU Langone Health
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 22-01058
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Deidentified quantitative assessment data will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research. Data will be stored in a data repository. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
IPD-delingstidsramme
Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
Tilgangskriterier for IPD-deling
The investigator who proposed to use the data will be granted access upon reasonable request. The data will be stored in a data repository.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .